tiprankstipranks
Eyenovia Inc (EYEN)
NASDAQ:EYEN
US Market
Holding EYEN?
Track your performance easily

Eyenovia (EYEN) Earnings Date & Reports

740 Followers

Earnings Data

Report Date
Mar 26, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
-$0.09
Last Year’s EPS
-$0.18
Same Quarter Last Year
Based on 4 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 12, 2024
|
% Change Since: -83.17%
|
Next Earnings Date:Mar 26, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant advances in product development and strategic partnerships but was overshadowed by financial challenges and a need for further capital. The company is making strong progress in product launches and regulatory approvals but faces ongoing financial hurdles that need addressing.
Company Guidance
During the Eyenovia third-quarter 2024 earnings call, the company provided significant guidance and updates on their strategic developments. Michael Rowe, the CEO, highlighted the nearing Phase III efficacy data readout for MicroPine, a product targeting pediatric progressive myopia, and the potential to access a multibillion-dollar market. Eyenovia is also advancing its next-generation Optejet technology, expected to enhance their profitability profile. The company is commercializing MydCombi and clobetasol, with the latter already placed in over 100 pharmacies. The CEO discussed the potential for the MicroPine NDA submission as soon as early 2026 if the ongoing Phase III CHAPERONE study yields positive results. Furthermore, the Gen 2 Optejet device could provide margins of up to 90%. Eyenovia's partnerships with Formosa, Senju, and SGN to address unmet needs in the dry eye market were also emphasized, alongside a licensing program with Arctic Vision in China and South Korea, potentially bringing in $37 million in future milestones. The company reported a net loss of $7.9 million for the quarter, with unrestricted cash at $7.2 million, reflecting ongoing strategic investments and commercialization efforts.
Significant Progress in MicroPine Development
Eyenovia is approaching a Phase III efficacy data readout for MicroPine, targeting a multibillion-dollar market for pediatric progressive myopia.
Launch of Clobetasol
Eyenovia launched clobetasol, an FDA-approved ophthalmic steroid, seeing strong interest and distribution in over 100 offices.
Expansion of MydCombi
MydCombi, based on Optejet technology, is now used in over 200 ophthalmology offices, with plans to expand to 200 more offices.
Strategic Partnerships and Collaborations
Established development collaborations with Formosa, Senju, and SGN for dry eye disease treatments leveraging Optejet technology.
Manufacturing and Regulatory Progress
Successful audits by the Nevada Board of Pharmacy and FDA, enabling manufacturing and distribution from the Reno facility.
---

Eyenovia (EYEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

EYEN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 26, 20252024 (Q4)
-0.09 / -
-0.18
Nov 12, 20242024 (Q3)
-0.13 / -0.11
-0.1838.89% (+0.07)
Aug 12, 20242024 (Q2)
-0.15 / -0.21
-0.16-31.25% (-0.05)
May 15, 20242024 (Q1)
-0.23 / -0.23
-0.15-53.33% (-0.08)
Mar 18, 20242023 (Q4)
-0.17 / -0.18
-0.17-5.88% (>-0.01)
Nov 13, 20232023 (Q3)
-0.18 / -0.18
-0.2114.29% (+0.03)
Aug 10, 20232023 (Q2)
-0.17 / -0.16
-0.2227.27% (+0.06)
May 11, 20232023 (Q1)
-0.19 / -0.15
-0.2437.50% (+0.09)
Mar 30, 20232022 (Q4)
-0.20 / -0.17
0.1-270.00% (-0.27)
Nov 10, 20222022 (Q3)
-0.20 / -0.21
-0.210.00% (0.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

EYEN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2024$0.50$0.41-18.00%
Aug 12, 2024$0.88$0.80-9.09%
May 15, 2024$1.06$0.82-22.64%
Mar 18, 2024$1.53$1.18-22.88%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Eyenovia Inc (EYEN) report earnings?
Eyenovia Inc (EYEN) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
    What is Eyenovia Inc (EYEN) earnings time?
    Eyenovia Inc (EYEN) earnings time is at Mar 26, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is EYEN EPS forecast?
          EYEN EPS forecast for the fiscal quarter 2024 (Q4) is -$0.09.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis